1. Direct thrombin inhibitors in acute coronary syndromes: principal results of a meta-analysis based on individual patients' data
- Author
-
Yusuf, S, Granger, C, Eikelboom, J, Mehta, S, Pogue, J, Tait, P, Behar, S, Benderly, M, Hod, H, Kaplinsky, E, Barrett, N, Bilke, R, Luz, M, Marhoefer, M, Roi, L, Trenery, D, Bittl, JA, Boersma, H, Flather, M, Baigent, C, Simoons, ML, Califf, R, Pieper, K, Topol, EJ, Weitz, J, Serruys, PW, White, HD, Neuhaus, KL, Zeymer, U, Simes, J, Close, P, Edwards, S, Gallo, P, Henis, M, Anand, S, Kimball, W, Meanwell, C, Villiger, J, Antman, EM, Braunwald, E, Gibson, M, Murphy, S, Grip, L, Held, P, Trialist, DTI, and Cardiology
- Subjects
medicine.medical_specialty ,medicine.medical_treatment ,Hirudin ,Glycine ,Myocardial Infarction ,Pharmacology ,Arginine ,Argatroban ,Antithrombins ,Piperidines ,Hirudin Therapy ,Internal medicine ,medicine ,Bivalirudin ,Humans ,Myocardial infarction ,Angina, Unstable ,Randomized Controlled Trials as Topic ,Sulfonamides ,business.industry ,Heparin ,Thrombin ,Percutaneous coronary intervention ,General Medicine ,Hirudins ,medicine.disease ,Peptide Fragments ,Recombinant Proteins ,Survival Rate ,Direct thrombin inhibitor ,Pipecolic Acids ,Cardiology ,business ,Oligopeptides ,medicine.drug ,Discovery and development of direct thrombin inhibitors - Abstract
BACKGROUND: To obtain more reliable and precise estimates of the effect of direct thrombin inhibitors in the management of acute coronary syndromes, including patients undergoing percutaneous coronary intervention, we undertook a meta-analysis based on individual patients' data from randomised trials comparing a direct thrombin inhibitor (hirudin, bivalirudin, argatroban, efegatran, or inogatran) with heparin. METHODS: We included trials that involved at least 200 patients. The primary efficacy outcome was death or myocardial infarction, and the primary safety outcome was major bleeding. Data from individual trials were combined by use of a modified Mantel-Haenszel method. FINDINGS: In 11 randomised trials, 35,970 patients were assigned up to 7 days' treatment with a direct thrombin inhibitor or heparin and followed up for at least 30 days. Compared with heparin, direct thrombin inhibitors were associated with a lower risk of death or myocardial infarction at the end of treatment (4.3% vs 5.1%; odds ratio 0.85 [95% CI 0.77-0.94]; p=0.001) and at 30 days (7.4% vs 8.2%; 0.91 [0.84-0.99]; p=0.02). This was due primarily to a reduction in myocardial infarctions (2.8% vs 3.5%; 0.80 [0.71-0.90]; p
- Published
- 2002